Relationship between Mechanisms, Bioavailibility, and Preclinical Chemopreventive Efficacy of Resveratrol: A Conundrum

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 10, 2003, Pages 953-957

  Gescher, Andreas J ^a   Steward, William P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EPIGALLOCATECHIN GALLATE; FLAVONOID; GENISTEIN; POLYPHENOL; QUERCETIN; RESVERATROL;

ANIMAL MODEL; CANCER MODEL; CANCER PREVENTION; CELL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; NOTE; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; HUMANS; NEOPLASMS; PALLIATIVE CARE; PHENOLS; RIBONUCLEOTIDE REDUCTASES; RODENTIA; STILBENES; VASODILATOR AGENTS;

EID: 0142243190     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (48)

1. Omenn, G. S. Chemoprevention of lung cancer: the rise and demise of β-carotene. Ann. Rev. Public Health, 19: 73-99, 1998.
2. Jang, M. S., Cai, E. N., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science (Wash. DC), 275: 218-220, 1997.
3. Gusman, J., Malonne, H., and Atassi, G. A. A re-appraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis (Lond.), 22: 1111-1117, 2001.
4. Fremont, L. Minireview-Biological effects of resveratrol. Life Sci., 66: 663-673, 2000.
5. Roemer, K., and Mahyar-Roemer, M. The basis for the chemopreventive action of resveratrol. Drugs Today, 38: 571-580, 2002.
6. Savouret, J. F., and Quesne, M. Resveratrol and cancer: a review. Biomed. Pharmacother., 54: 84-87, 2002.
7. Bhat, K. P. L., and Pezzuto, J. M. Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci., 957: 210-229, 2002.
8. Chang, T. K., Lee, W. B., and Ko, H. H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can. J. Physiol. Pharmacol., 78: 874-881, 2000.
9. Basly, J. P., Marre-Fournier, F., LeBail, J. C., Habrioux, G., and Chulia, A. J. Estrogenic./antiestrogenic and scavanging properties of (E)- and (Z)-resveratrol. Life Sci., 66: 769-777, 2000.
10. Goldberg, D. M., Yan, J., and Soleas, G. J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem., 36: 79- 87, 2003.
11. Juan, M. E., Buenafuente, J., Casals, I., and Planas, J. M. Plasmatic levels of trans-resveratrol in rats. Food Res. Int., 35: 195-199, 2002.
12. Asensi, M., Medina, I., Ortega, A., Carretero, J., Bano, M. C., Obrador, E., and Estrela, J. M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med., 33: 387-398, 2002.
13. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J-P., and Ducharme, M. P. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther., 302: 369-373, 2002.
14. Soleas, G. J., Angelini, M., Grass, L., Diamandis, E. P., and Goldberg, D. M. Absorption of trans-resveratrol in rats. Methods Enzymol., 335: 145-154, 2001.
15. 14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci., 72: 2219-2233, 2003.
16. Bertelli, A. A. E., Giovanni, L., Stradi, R., Urien, S., Tillement, J-P., and Bertelli, A. Kinetics of trans-and cis- resveratrol (3, 4′, 5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharm. Res., 16: 77-81, 1996.
17. Andlauer, W., Kolb, J., Siebert, K., and Furst, P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res., 26: 47-55, 2000.
18. Yu, C. W., Shin, Y. G., Chow, A., Li, Y. M., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., and Van Breemen, R. B. Human, rat, and mouse metabolism of resveratrol. Pharm. Res., 19: 1907-1914, 2002.
19. Kuhnle, G., Spencer, J. P. E., Chowrimootoo, G., Schroeter, H., Debnam, E. S., Srai, S. K. S., Rice-Evans, C., and Hahn, U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun., 272: 212-217, 2000.
20. De Santi, C., Pietrabissa, A., Mosca, F., and Pacifici, G. M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica, 30: 857-866, 2000.
21. De Santi, C., Pietrabissa, A., Mosca, F., and Pacifici, G. M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica, 30: 1047-1054, 2000.
22. Bhat, K. P. L., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res., 61: 7456-7463, 2001.
23. Schneider, Y., Duranton, B., Gosse, F., Schleiffer, R., Seiler, N., and Raul, F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr. Cancer, 39: 102-107, 2001.
24. Ziegler, C. C., McEntee, M. F., Hansen-Petrik, M., Johnson, B. T., and Whelan, J. In vivo effects of trans-resveratrol on intestinal tumorigenesis. FASEB J., 15: A617, 2001.
25. Gignac, E. A., and Bourquin, L. D. Influence of resveratrol and sulindac on intestinal tumor numbers in Min mice. FASEB J., 15: A630, 2001.
26. Tessitore, L., Davit, A., Sarotto, I., and Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis (Lond.), 21: 1619-1622, 2000.
27. Li, Z. G., Hong, T., Shimada, Y., Komoto, I., Kawabe, A., Ding, Y., Kaganoi, J., Hashimoto, Y., and Imamura, M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis (Lond.), 23: 1531-1536, 2002.
28. Banerjee, S., Bueso-Ramos, C., and Aggarwal, B. B. Suppression of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κ B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 62: 4945-4954, 2002.
29. Corpet, D. E., and Pierre, F. Point: from animal models to prevention of colon cancer: systematic review of chemoprevention in Min mice and choice of the model system. Cancer Epidemiol. Biomark. Prev., 12: 391-400, 2003.
30. Bruce, W. R. Counterpoint: from animal models to prevention of colon cancer: criteria for proceeding from preclinical studies and choice of models for prevention studies. Cancer Epidemiol. Biomark. Prev., 12: 401-404, 2003.
31. Dale, I. L., and Gescher, A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int. J. Cancer, 43: 158-163, 1989.
32. Wieder, T., Prokop, A., Bagci, B., Essmann, F., Bernicke, D., Schulze-Osthoff, K., Dorken, B., Schmalz, H. G., Daniel, P. T., and Henze, G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary leukemic lymphoblasts. Leukemia (Baltimore), 15: 1735-1742, 2001.
33. Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., and Burke, M. D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer, 86: 774-778, 2002.
34. Surh, Y. J., Hurh, Y. J., Kang, J. Y., Lee, E., Kong, G., and Lee, S. J. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett., 140: 1-10, 1999.
35. Clement, M. V., Hirpara, J. L., Chawdhury, S. H., and Pervaiz, S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD96 signaling-dependent apoptosis in human tumor cells. Blood, 92: 996-1002, 1998.
36. Mahyar-Roemer, M., Katsen, A., Mestres, P., and Roemer, K. Resveratrol induces colon tumor cell apoptosis independently of p53 and preceded by epithelial differentiation, mitochondrial proliferation and membrane potential collapse, Int. J. Cancer, 94: 615-622, 2001.
37. Martinez, J., and Moreno, J. J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol., 59: 865-870, 2000.
38. Ciolino, H. P., and Yeh, G. C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol., 56: 760-767, 1999.
39. Chan, W. K., and Delucchi, A. B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci., 67: 3103-3112, 2000.
40. She, Q. B., Bode, A. M., Ma, W. Y., Chen, N. Y., and Dong, Z. G. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res., 61: 1604-1610, 2001.
41. She, Q. B., Huang, C. S., Zhang, Y. G., and Dong, Z. G. Involvement of c-jun NH2-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol. Carcinog., 33: 244-250, 2002.
42. Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M. S., Pezzuto, J. M., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 273: 21875-21882, 1998.
43. Ahmad, N., Adhami, V. M., Afaq, F., Feyes, D. K., and Mukhtar, H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res., 7: 1466-1473, 2001.
44. Delmas, D., Passilly-Degrace, P., Jannin, B., Malki, M. C., and Latruffe, N. Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. Int. J. Mol. Med., 10: 193-199, 2002.
45. Atten, M. J., Attar, B. M., Milson, T., and Holian, O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol., 62: 1423-1432, 2001.
46. Haworth, R. S., and Avkiran, M. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol., 62: 1647-1651, 2001.
47. Holmes-McNary, M., and Baldwin, A. S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the I κ B kinase. Cancer Res., 60: 3477-3483, 2000.
48. Manna, S. K., Mukhopadhyay, A., and Aggarwal, B. B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B. activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 164: 6509-6519, 2000.